- Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
- New Phase III Study with Nintedanib currently enrolling patients with Systemic Sclerosis and Lung Fibrosis
- Preliminary Study of Triciribine Shows Treatment and Possible Reversal of Pulmonary Fibrosis and Pulmonary Hypertension in Mice
- New Drug Approved May 2015 for the Maintenance of COPD: Stiolto Respimat
- Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease
- Plasma Fibrinogen Approved as a Biomarker for COPD
- Randomized, Double-Blind Study Demonstrates Effectiveness of Augmentation Therapy to Treat Severe α1 Antitrypsin Deficiency
